3.4.22.41	1,10-phenanthroline	15.28% inhibition at 0.1 mM	62	
3.4.22.41	antipain	complete inhibition at 0.1 mM	520	
3.4.22.41	Aprotinin	36.94% inhibition at 0.1 mM	405	
3.4.22.41	Chloroquine	-	1439	
3.4.22.41	chymostatin	35.42% inhibition at 0.1 mM	511	
3.4.22.41	Co2+	6.85% residual activity at 5 mM	23	
3.4.22.41	Cu2+	11.6% residual activity at 5 mM	19	
3.4.22.41	cystatin B	-	9663	
3.4.22.41	E-64	56.3% inhibition at 0.1 mM	559	
3.4.22.41	E-64	effective inhibition	559	
3.4.22.41	E-64	-	559	
3.4.22.41	EDTA	6.52% inhibition at 0.1 mM	21	
3.4.22.41	EGTA	4.72% inhibition at 0.1 mM	173	
3.4.22.41	Hg2+	0.81% residual activity at 5 mM	33	
3.4.22.41	JPM565	radioactive-labeling by 125I, irrevrsible inhibitor of papin-type cathepsins, active site labeling	132532	
3.4.22.41	leupeptin	complete inhibition at 0.1 mM	217	
3.4.22.41	additional information	downregulation of cathepsin F mRNA by E-64d; treatment with retinol/palmitic acid increases mRNA-level of cystatin B coupled with decrease in cathepsin F activity; treatment with retinol/palmitic acid increases mRNA-level of cystatin C coupled with decrease in cathepsin F activity	2	
3.4.22.41	additional information	not inhibited by pepstatin A	2	
3.4.22.41	additional information	the prodomain effectively inhibits the enzyme in which the ERFNAQ motif plays a critical role in the inhibition, but the GTFD motif is also required for complete inhibition	2	
3.4.22.41	morpholine urea-Leu-homophenylalaninevinyl sulfone-phenyl	potent and irreversible inhibitor of cysteine proteases	47985	
3.4.22.41	morpholine urea-Leu-homophenylalaninevinyl sulfone-phenyl	-	47985	
3.4.22.41	NEM	44.59% inhibition at 0.1 mM	89	
3.4.22.41	phenylmethylsufonyl fluoride	13.22% inhibition at 0.1 mM	160124	
3.4.22.41	SDS	complete inhibition at 0.05% (w/v)	124	
3.4.22.41	trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane	i.e. E-64	1306	
3.4.22.41	trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane	-	1306	
3.4.22.41	Z-VAD(OMe)-fluoromethylketone	-	201886	
3.4.22.41	Zn2+	5.94% residual activity at 1 mM	14